Last reviewed · How we verify

NCT04392323

Incidence of COVID-19 Test Conversion in Post-surgical Patients

Completed NA Last updated 8 November 2021
What this trial tests

NA trial testing COVID-19 PCR and Serology in Sars-CoV2 in 111 participants. Completed in 4 October 2020.

Timeline
13 May 2020
Primary endpoint
1 October 2020
4 October 2020

Quick facts

Lead sponsorNorthwell Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment111
Start date13 May 2020
Primary completion1 October 2020
Estimated completion4 October 2020
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwell Health — full company profile →

Who can join

18 and older, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 cases begins to decrease and hospital volume improves we need to ensure the safety of our patients planning surgical procedures. However, at this time there is a scarcity of data regarding the COVID-19 test conversion rate in surgical patients. Our goal is to determine the COVID-19 test conversion rate in these patients to better guide strategies for restarting surgical care in a large-scale pandemic. Patients will be routinely tested with serology and PCR for COVID-19 24-48 hours prior to their scheduled surgery. Those who provide informed consent will be re-tested 12-16 days after discharge from the hospital to determine any potential nosocomial infection rate. Patients will also answer a few questions during their retest to allow the study team to gauge exposure risk postoperatively after leaving the hospital.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Nosocomial COVID-19 infection in women undergoing elective cesarean delivery: a prospective cohort study.
    Nizam A, Nimaroff ML, Menzin AW, Goldberg GL, et al · · 2022 · cited 1× · PMID 34543753 · DOI 10.1016/j.ajogmf.2021.100490

Verify or expand the search:

Other recruiting trials for Sars-CoV2

Currently open trials in the same condition.

Other Northwell Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04392323.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing